

19 May 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: the life of a blockbuster; blockbusters by indication; gene therapy struggles; sun shines on AstraZeneca and GSK; and Korean ventures look to Japan.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 17 May 2024, including: the life of a blockbuster; blockbusters by indication; gene therapy struggles; sun shines on [AstraZeneca PLC](#) and [GSK plc](#); and Korean ventures look to Japan.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[The Life Of A Blockbuster](#)" - Scrip, 10 May, 2024.)

(Also see "[Blockbusters By Indication: More Begets More](#)" - Scrip, 13 May, 2024.)

(Also see "[Gene Therapy Q1 Roundup: The Struggle Is Real](#)" - Scrip, 9 May, 2024.)

(Also see "[Stock Watch: The Sun Shines On AstraZeneca And GSK](#)" - Scrip, 14 May, 2024.)

(Also see "[Japan Looks For Role As Korean Ventures' New Step To Global Market](#)" - Scrip, 14 May, 2024.)

[Click here to explore this interactive content online](#) 